POMPANO BEACH, Fla., Oct. 31, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced top-line results of the Company’s clinical trial evaluating BioRetain® – Processed Amnion Chorion (BR-AC) versus standard of care for patients with non-healing diabeti…

You can read the full content here